Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Cynthia G. Leichman"'
Autor:
Peter J. O'Dwyer, A. Bapsi Chakravarthy, Patrick J. Flynn, James D. Brierley, Daniel G. Haller, Roger Santala, Nicholas J. Petrelli, David Cella, Cynthia G. Leichman, Al B. Benson, Rashid A. Awan, Mary F. Mulcahy, Christine Cripps, Timothy E. O'Brien, Frank A. Sinicrope, Neal J. Meropol, Joel E. Tepper, James N. Atkins, Bruce J. Giantonio, Jeff A. Sloan, Robert B. Catalano, Edith P. Mitchell, Robert B. Diasio, Elin R. Sigurdson, John R. Weis, Paul J. Catalano, Lynne I. Wagner, Fengmin Zhao, Stanley R. Hamilton
Publikováno v:
Oncologist
Background The addition of bevacizumab to chemotherapy improved outcomes for patients with metastatic colon cancer. E5204 was designed to test whether the addition of bevacizumab to mFOLFOX6, following neoadjuvant chemoradiation and definitive surger
Autor:
Philip J. Gold, Gershon Y. Locker, Jordan Berlin, Bruce Boman, Wells A. Messersmith, Stan R. Hamilton, Cynthia G. Leichman, Deirdre Jill Cohen, Lawrence Leichman, Susan Groshen, Emily Chan, Anitra Fielding, Steven J. Cohen, Bert H. O'Neil, Howard S. Hochster, Heinz-Josef Lenz, Ronald C. Cason
Publikováno v:
The Oncologist. 21:172-177
Background Effective new agents for patients with colorectal cancer (CRC) with disease progression during standard therapy regimens are needed. We hypothesized that poly ADP ribose polymerase (PARP) inhibitor therapy in patients with CRC and ineffici
Autor:
Aram F. Hezel, Katherine A. Guthrie, Cynthia G. Leichman, Howard S. Hochster, Heinz-Josef Lenz, Matthew A. Beldner, Shannon McDonough, Mario R. Velasco, Kevin G. Billingsley, Stephen R. Smalley, Charles D. Blanke
Background Neoadjuvant chemoradiation (NCRT) is standard treatment for locally advanced rectal cancer. Pathologic complete response (pCR) has associated with improved survival. In modern phase III trials of NCRT, pCR ranges from 10% to 20%. Cetuximab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f883377d89e50a9ba6df5e922e379b0d
https://europepmc.org/articles/PMC6598683/
https://europepmc.org/articles/PMC6598683/
Autor:
Ling Ming Tseng, Cynthia G. Leichman, Alexy Manikhas, Cristina Saura, Lokanatha Dasappa, Shona Nag, David R. Liu, W. Fraser Symmans, Mario Campone, Pralay Mukhopadhyay, Guan Xing, Fernando Hurtado de Mendoza, Raju Titus Chacko, Christine Horak, Stephen Chan, Peter A. Fasching, Lajos Pusztai
Publikováno v:
The Oncologist. 18:787-794
Background. This randomized phase II trial was designed to compare the rate of pathologic complete response (pCR) induced by neoadjuvant cyclophosphamide plus doxorubicin (AC) followed by ixabepilone or paclitaxel in women with early stage breast can
Autor:
Nicholas J. Sanfilippo, Cynthia G. Leichman, Danielle S. Bitterman, D. Grew, Harvey G. Moore, Lawrence Leichman, K.L. Du
Publikováno v:
Diseases of the colon and rectum. 58(12)
HIV status may affect outcomes after definitive chemoradiotherapy for anal cancer.Here, we report a large series in the highly active antiretroviral therapy era comparing outcomes between HIV-positive and HIV-negative patients with anal cancer.This w
Autor:
Donald Woytowitz, Arthur M. Krieg, J. Mezger, Vera Hirsh, Donald Gravenor, Christian Manegold, Mohammed J Al-Adhami, David Robert John Readett, Gary Albert, Cynthia G. Leichman
Publikováno v:
Journal of Clinical Oncology. 26:3979-3986
Purpose This study assessed the efficacy of the combination of standard taxane plus platinum chemotherapy with the synthetic Toll-like receptor 9–activating oligodeoxynucleotide PF-3512676 in patients with non–small-cell lung cancer (NSCLC). Pati
Autor:
Danielle S, Bitterman, David, Grew, Ping, Gu, Richard F, Cohen, Nicholas J, Sanfilippo, Cynthia G, Leichman, Lawrence P, Leichman, Harvey G, Moore, Heather T, Gold, Kevin L, Du
Publikováno v:
Journal of gastrointestinal oncology. 6(5)
To compare clinical and treatment characteristics and outcomes in locally advanced anal cancer, a potentially curable disease, in patients referred from a public or private hospital.We retrospectively reviewed 112 anal cancer patients from a public a
Publikováno v:
Seminars in Oncology. 30:11-18
This article gives a brief discussion of "state-of-the-art" therapeutic strategies for esophageal and gastroesophageal junction tumors, with an emphasis on combined-modality therapy. In addition, we review the results of a multimodality trial conduct
Autor:
Lawrence Leichman, Cynthia G. Leichman
Publikováno v:
European Journal of Surgery. 167:43-48
Autor:
Franco M. Muggia, Christine Upchurch, Barbara McKnight, Cynthia G. Leichman, Laura C. Lovato, Wendy A. James, Julia Sawyers Triplett, Leora Tanaka, Frank L. Meyskens, Carol M. Moinpour, Martha Lennard
Publikováno v:
Moinpour, CM; Triplett, JS; McKnight, B; Lovato, LC; Upchurch, C; Leichman, CG; et al.(2000). Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. PSYCHO-ONCOLOGY, 9(4), 340-354. doi: 10.1002/1099-1611(200007/08)9:4<340::AID-PON466>3.3.CO;2-6. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/3314v2s8
Effects of variations in agent, dose, and route of treatment administration on patient reported quality of life (QOL) were examined for 279 patients enrolled on a seven-arm randomized clinical trial (S8905) of 5-FU and its modulation for advanced col